News

Team approach to lupus care being tested at Duke Health

A new project incubating at Duke Advanced Practice Provider Leadership Institute (APPLI) seeks to foster a team approach to lupus care at Duke Health in Durham, North Carolina. The project is being led by Keisha-Gaye O’Garo, a clinical psychologist, and Karen McCain, a psychiatric nurse practitioner, both from…

Phase 3 trials of ianalumab for SLE, lupus nephritis now enrolling

Three new Phase 3 clinical trials testing the experimental therapy ianalumab in people with systemic lupus erythematosus (SLE) and lupus nephritis are now recruiting patients. All three trials are being sponsored by Novartis, the company developing ianalumab. Lupus Therapeutics, the clinical research affiliate of the Lupus Research Alliance,…

Lupkynis helps protect kidneys with lupus nephritis and high proteinuria

Lupkynis (voclosporin) combined with background lupus treatments better preserved kidney function among a subgroup of lupus nephritis patients with particularly high protein levels in the urine (proteinuria) compared with background therapy alone. Notably, these benefits were observed regardless of patients’ baseline demographic or clinical characteristics, and they were…

Upadacitinib reduces SLE disease activity: Phase 2 trial data

A year of treatment with upadacitinib led to significant disease activity reductions for people with systemic lupus erythematosus (SLE), according to data from the Phase 2 SLEek trial. It was similarly effective when used with the experimental treatment elsubrutinib, in a combination called ABBV-599, the researchers found. These and…

KYV-101 CAR-T cell therapy for lupus nephritis on FDA fast track

KYV-101, an investigational cell therapy from Kyverna Therapeutics, has been granted a fast track designation by the U.S. Food and Drug Administration (FDA) for the treatment of refractory lupus nephritis — a serious lupus complication characterized by kidney damage. Fast track status is granted to experimental therapies for…

Lupus Landmark Study launched to improve research, personalized care

The Lupus Research Alliance (LRA) and its clinical research affiliate, Lupus Therapeutics, have launched the largest, long-term prospective observational study in lupus with the goal of developing new, personalized treatments for the chronic immune system disorder. The Lupus Landmark Study is a key part of Lupus…

Lupus awareness campaign aims to reach Latinas and Black women

The Lupus Foundation of America (LFA) has launched a new awareness campaign to help Black/African American and Hispanic/Latina women recognize the signs and symptoms of lupus. Dubbed “Be Fierce. Take Control,” the digital awareness campaign especially aims to reach young, undiagnosed women among this population, among whom…